Stryker (SYK) Stock Plummets to 52-Week Low Following Wells Fargo Downgrade

Key Takeaways

Table of Contents

Stryker (SYK) shares plummeted 8.9% Wednesday, reaching a 52-week low of $275.10
Wells Fargo slashed its price objective from $418 down to $348, maintaining Overweight stance
The investment bank reduced 2026 revenue projections to $27,209M, falling short of management’s guidance
Wall Street maintains a “Moderate Buy” rating with consensus price target at $386.28
Company insiders offloaded more than 351,000 shares totaling approximately $118.2 million recently

Medical device manufacturer Stryker (SYK) experienced a sharp decline Wednesday, falling 8.9% to close at $276.16 after hitting an intraday 52-week low of $275.10. The stock now trades significantly beneath both its 50-day moving average of $327.52 and 200-day moving average of $328.30.

Stryker Corporation, SYK

The sharp downturn followed Wells Fargo‘s decision to reduce its price objective on the medical technology company to $348 from a previous $418, despite maintaining its Overweight recommendation. This adjustment came on the heels of Stryker’s presentation at the 2026 Wells Fargo Healthcare Conference held in Boston, where CFO Preston Wells and VP of Investor Relations Nick Mead spoke on behalf of the organization.

The investment firm decreased its 2026 revenue projection to $27,209 million from a prior estimate of $27,325 million. This revision suggests organic expansion of 8.1%, falling short of Stryker’s internal forecast range of 8.3% to 9.3%.

Additionally, Wells Fargo reduced its third-quarter organic growth forecast to 8.9% from 10.1%. The firm pointed to ongoing challenges in peripheral vascular product lines and hip and knee replacement divisions across global markets through year-end.

The adjusted earnings per share estimate for 2026 was trimmed to $14.95 from $15.02, positioning at the lower boundary of Stryker’s guided range of $14.95 to $15.10.

Wall Street Maintains Optimistic Outlook

Notwithstanding the recent pressure, analyst sentiment toward Stryker remains largely favorable. The medical device maker holds a “Moderate Buy” consensus among Wall Street observers, featuring one Strong Buy recommendation, seventeen Buy ratings, and six Hold ratings.

The consensus price objective stands at $386.28, representing substantial upside from current trading levels. Piper Sandler retained its Overweight designation while reducing its target to $390. JPMorgan similarly lowered its objective to $350 while preserving its Overweight view. Leerink Partners continues with an Outperform rating and $407 price target.

Stryker most recently disclosed Q2 2026 financial results on July 30th. The company posted adjusted earnings of $3.69 per share, surpassing analyst expectations of $3.49 by $0.20. Total revenue reached $6.59 billion, marginally exceeding the $6.58 billion consensus forecast.

Second-quarter revenue increased 9.4% compared to the year-ago period. Earnings per share expanded 18% versus the corresponding quarter last year.

In response to these results, Wolfe Research elevated its price target to $375 from $350 while maintaining an Outperform recommendation. Citizens took a more cautious approach, trimming its target to $400 from $440, highlighting supply chain disruptions and a cybersecurity incident that occurred earlier in the fiscal year.

Notable Insider Transactions

Insider trading activity has attracted investor attention. Over the past three months, company insiders disposed of 351,267 shares valued at roughly $118.2 million.

Insider Debra King divested 826 shares on August 18th at a price of $336.30 per share. Dylan Crotty sold 441 shares on August 21st at $328.61 per share. Corporate insiders collectively maintain ownership of 4.60% of outstanding shares.

Among institutional investors, California State Teachers Retirement System significantly expanded its position during Q2. The pension fund currently owns 163.4 million shares with an estimated value of approximately $51.4 billion.

The medical device company announced a quarterly dividend distribution of $0.88 per share, scheduled for payment on October 30th to shareholders registered as of September 30th. The annual dividend totals $3.52, representing a yield of approximately 1.3%.

Management has established full-year 2026 earnings guidance between $14.95 and $15.10 per share. The analyst community projects average earnings of $15.03 for the current fiscal year.

✨ Limited Time Offer